Emergent BioSolutions Inc. (EBS) 8-K Current Report: March 3, 2026
Filed: March 3, 2026
Health Care
Pharmaceutical PreparationsEmergent BioSolutions Inc. (EBS) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
Emergent BioSolutions Inc. 8-K Mar 3, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • John D. Fowler, Jr. appointed Class II director effective March 1, 2026; independent under NYSE standards, joining Audit and Finance Committee
- • Initial RSU grant valued at $270,000, vesting in 3 equal annual installments over 3 years
- • Annual compensation: $70,000 cash retainer + $15,000 Audit Committee retainer + $270,000 equity award (75% RSUs / 25% options)
- • No related-party conflicts disclosed; appointment not tied to any third-party arrangement
Item 7.01 · Regulation FD Disclosure
- • Press release issued March 3, 2026 announcing appointment of Mr. Fowler, furnished as Exhibit 99.1
- • Reg FD disclosure signals leadership change deemed material enough for broad investor communication
Other Emergent BioSolutions Inc. 8-K Filings
Get deeper insights on Emergent BioSolutions Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.